immunology of hcv and hbv in renal failure and transplantation
نویسندگان
چکیده
منابع مشابه
Editorial: Recent Advances in HBV and HCV Immunology
Viral hepatitis is a major public health problem. While a prophylactic vaccine is now available for hepatitis B virus (HBV), an estimated 240–350 million people worldwide are persistently infected with HBV (1–3). There is not yet an approved vaccine to prevent hepatitis C virus (HCV) infection, and between 130 and 200 million people are believed to be chronically infected worldwide (4–6). Untre...
متن کاملManagement of Recurrent HCV and HBV Infections after Liver Transplantation
Sequels of chronic HCV infection such as end-stage liver cirrhosis and hepatocellular carcinoma (HCC) are the leading indications for liver transplantation (LT) in Europe and in the United States. According to the United Network for Organ Sharing (UNOS) database the proportion of transplants performed due to the decompensated cirrhosis secondary to hepatitis C infection slightly declined in the...
متن کاملHEARING LOSS IN CHRONIC RENAL FAILURE AND CHANGES WITH KIDNEY TRANSPLANTATION
Loss of hearing is a known problem in patients with chronic renal failure, occurring in 40-XO% of cases and being most often of the high frequency sensorineural type. We performed a study on 50 patients with this disease, including 20 who had undergone a successful kidney transplantation. Our results show an 80% incidence of hearing loss in these patients and a chance of improvement in at l...
متن کاملsynthesis of sulfides from alcohols and thiols in solvent-freeconditions and deoxygenation of sulfoxides
کاتالیست یک سنتز جدید برای تیواترها توصیف شده است. واکنش الکل ها با آریل، هتروآریل و آلکیل تیو ل ها درحضور 1،3،5- تری آزو- 2،4،6- تری فسفرین-2،2،4،4،6،6 هگزاکلراید ((tapc به عنوان یک کاتالیست موُثر، بازده های خوب تا عالی از تیواترها را حاصل می کند. علاوه براین، واکنش تحت شرایط بدون فلز و بدون حلال پیش می رود، بنابراین یک مکمل جالب برای روش های شناخته شده سنتز تیواترها ارائه می دهد. یک مکانیسم ا...
15 صفحه اولHBV and HCV Therapy
One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response ...
متن کاملPARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort
Background: The seroprevalence of human parvovirus-4 (PARV4) varies considerably by region. In sub-Saharan Africa, seroprevalence is high in the general population, but little is known about the transmission routes or the prevalence of coinfection with blood-borne viruses, HBV, HCV and HIV. Methods: To further explore the characteristics of PARV4 in this setting, with a particular focus on the...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۷، شماره ۲، صفحات ۹۳-۱۰۱
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023